RNA editing with CRISPR-Cas13

RNA editing with CRISPR-Cas13

Nucleic acid editing holds promise for treating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescued to yield functional protein products. Type VI CRISPR-Cas systems contain the programmable single-effector RNA-guided ribonuclease Cas13. We profiled type VI...

Full description

Bibliographic Details
Main Authors: Cox, David Benjamin Turitz (Author), Gootenberg, Jonathan S. (Author), Abudayyeh, Omar O. (Author), Franklin, Brian (Author), Kellner, Max J. (Author), Joung, Julia (Author), Zhang, Feng (Author)
Other Authors: Broad Institute of MIT and Harvard (Contributor), McGovern Institute for Brain Research at MIT (Contributor), Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Harvard University- (Contributor)
Format: Article
Language:English
Published: American Association for the Advancement of Science (AAAS), 2020-05-07T12:51:49Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items